166 related articles for article (PubMed ID: 9605644)
1. Cost-minimization analysis of prophylactic granulocyte colony-stimulating factor after induction chemotherapy in children with non-Hodgkin's lymphoma.
Rubino C; Laplanche A; Patte C; Michon J
J Natl Cancer Inst; 1998 May; 90(10):750-5. PubMed ID: 9605644
[TBL] [Abstract][Full Text] [Related]
2. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy.
Zagonel V; Babare R; Merola MC; Talamini R; Lazzarini R; Tirelli U; Carbone A; Monfardini S
Ann Oncol; 1994; 5 Suppl 2():127-32. PubMed ID: 7515645
[TBL] [Abstract][Full Text] [Related]
3. Cost-benefit analysis of prophylactic granulocyte colony-stimulating factor during CHOP antineoplastic therapy for non-Hodgkin's lymphoma.
Dranitsaris G; Altmayer C; Quirt I
Pharmacoeconomics; 1997 Jun; 11(6):566-77. PubMed ID: 10173030
[TBL] [Abstract][Full Text] [Related]
4. Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology.
Patte C; Laplanche A; Bertozzi AI; Baruchel A; Frappaz D; Schmitt C; Mechinaud F; Nelken B; Boutard P; Michon J
J Clin Oncol; 2002 Jan; 20(2):441-8. PubMed ID: 11786572
[TBL] [Abstract][Full Text] [Related]
5. Cost benefit and clinical efficacy of low-dose granulocyte colony-stimulating factor after standard chemotherapy in patients with non-Hodgkin's lymphoma.
Hashino S; Morioka M; Irie T; Shiroshita N; Kawamura T; Suzuki S; Iwasaki H; Umehara S; Kakinoki Y; Kurosawa M; Kahata K; Izumiyama K; Kobayashi H; Onozawa M; Takahata M; Fujisawa F; Kondo T; Asaka M
Int J Lab Hematol; 2008 Aug; 30(4):292-9. PubMed ID: 18665826
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of white blood cell growth factor use among a large nationwide cohort of elderly non-Hodgkin's lymphoma patients treated with chemotherapy.
Gruschkus SK; Lairson D; Dunn JK; Risser J; Du XL
Value Health; 2011; 14(2):253-62. PubMed ID: 21402294
[TBL] [Abstract][Full Text] [Related]
7. Low-dose granulocyte colony-stimulating factor overcomes neutropenia in the treatment of non-Hodgkin's lymphoma with higher cost-effectiveness.
Hara T; Tsurumi H; Kasahara S; Kanemura N; Yoshikawa T; Goto N; Kojima Y; Yamada T; Sawada M; Takahashi T; Oyama M; Tomita E; Moriwaki H
Int J Hematol; 2005 Dec; 82(5):430-6. PubMed ID: 16533747
[TBL] [Abstract][Full Text] [Related]
8. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.
Souêtre E; Qing W
Pharmacoeconomics; 1994; 6 Suppl 2():36-43. PubMed ID: 10172484
[TBL] [Abstract][Full Text] [Related]
9. Granulocyte colony stimulating factor (G-CSF) as adjunct therapy in relapsed-resistant high-grade non-Hodgkin's lymphoma.
Zinzani PL; Martelli M; Tura S; Mandelli F
Haematologica; 1993; 78(1):40-3. PubMed ID: 7684011
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.
Lee SM; Radford JA; Dobson L; Huq T; Ryder WD; Pettengell R; Morgenstern GR; Scarffe JH; Crowther D
Br J Cancer; 1998 Apr; 77(8):1294-9. PubMed ID: 9579836
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of prophylactic granulocyte colony stimulating factor during chemotherapy in elderly patients with aggressive non-Hodgkin's lymphoma.
Doorduijn JK; Buijt I; van der Holt B; van Agthoven M; Sonneveld P; Uyl-de Groot CA
Haematologica; 2004 Sep; 89(9):1109-17. PubMed ID: 15377472
[TBL] [Abstract][Full Text] [Related]
12. Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.
Yakushijin Y; Shikata H; Takaoka I; Horikawa T; Takeuchi K; Yamanouchi J; Azuma T; Narumi H; Hato T; Yasukawa M
Int J Clin Oncol; 2011 Apr; 16(2):118-24. PubMed ID: 20924633
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of prophylactic G-CSF after mini-BEAM salvage chemotherapy for Hodgkin's and non-Hodgkin's lymphoma.
Dranitsaris G; Sutcliffe SB
Leuk Lymphoma; 1995 Mar; 17(1-2):139-45. PubMed ID: 7539658
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia.
Delorme J; Badin S; Le Corroller AG; Auvrignon AA; Auclerc MF; Gandemer V; Bordigoni P; Lamagnere JP; Demeocq F; Perel Y; Berthou C; Bauduer F; Pautard B; Vannier JP; Braguer D; Leblanc T; Leverger G; Baruchel A; Michel G
J Pediatr Hematol Oncol; 2003 Jun; 25(6):441-7. PubMed ID: 12794521
[TBL] [Abstract][Full Text] [Related]
15. [Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
Oyama A; Ota K; Asano S; Takaku F; Miyazaki T; Uzuka Y; Omine M; Furusawa S; Hirashima K; Sanpi K
Nihon Gan Chiryo Gakkai Shi; 1990 Aug; 25(8):1619-34. PubMed ID: 1700040
[TBL] [Abstract][Full Text] [Related]
16. [A double-blind, cross-over clinical trial of recombinant human G-CSF on neutropenia induced by chemotherapy for non-Hodgkin's lymphoma].
Oyama A; Ota K; Asano S; Takaku F; Yoshida Y; Uzuka Y; Omine M; Furusawa S; Takatani O; Sawada U
Nihon Gan Chiryo Gakkai Shi; 1990 Oct; 25(10):2533-48. PubMed ID: 1702132
[TBL] [Abstract][Full Text] [Related]
17. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study.
Heath JA; Steinherz PG; Altman A; Sather H; Jhanwar S; Halpern S; Pieters R; Shah N; Steinherz L; Tannous R; Terry W; Trigg ME;
J Clin Oncol; 2003 Apr; 21(8):1612-7. PubMed ID: 12697887
[TBL] [Abstract][Full Text] [Related]
18. Granulocyte colony-stimulating factor in neutropenic, pediatric solid tumor patients following chemotherapy.
Ayan I; Kebudi R; Doğan S; Tokuç G; Görgün O
Pediatr Hematol Oncol; 1996; 13(5):417-24. PubMed ID: 10897813
[TBL] [Abstract][Full Text] [Related]
19. CD64 surface expression on neutrophils and monocytes is significantly up-regulated after stimulation with granulocyte colony-stimulating factor during CHOP chemotherapy for patients with non-Hodgkin's lymphoma.
Kakinoki Y; Kubota H; Yamamoto Y
Int J Hematol; 2004 Jan; 79(1):55-62. PubMed ID: 14979480
[TBL] [Abstract][Full Text] [Related]
20. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
Bobey N; Woodman RC
Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
